Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 26, 2001

View Archived Issues

NCX-2111: a new NicOx NO-releasing compound for micturition disorders

Multicenter clinical trial of NMP22 BladderChek begins

FDA licenses first nucleic acid test systems for screening plasma donors

Pharmacokinetics and tolerability of multiple i.v. doses of daptomycin

Interactions of new drug for ADHD with other commonly used medications tested clinically

Data related to PK/PD of roxifiban discussed at ACCP meeting

CDP-840 attenuates increased TNF-alpha synthesis in healthy subjects

CAT antibody displays human eotaxin-neutralizing activity in vitro and in vivo

Vertex to focus on development of second-generation p38 MAP kinase inhibitors

H1 receptor antagonist with analgesic and antiinflammatory properties

Canadian authorities approve Gleevec following priority review

New drug for improving ED filed for approval in U.S., Mexico

Forbes' cholesterol-lowering pharmaceutical advances to clinical trials in Europe

Potential of Ono-4817 in osteoarthritis Rx discussed in Edinburgh

Superior efficacy demonstrated for SB-265610 compared to 5-ASA in experimental colitis model

Phase III multinational clinical trial of Surfaxin launched in IRDS

Supplemental development program announced for oral renin inhibitor aliskiren

COPD the third indication to be explored for ABX-IL-8

BLA filed by Cangene for antihepatitis B product

Duphar reports preparation and use of new dopamine D4 agonists

Bax inhibitors from ARS associated with improved neuronal survival

Substituted pyridines with the ability to control synaptic transmission

FibroGen describes new compounds for fibrotic disorders

Inhibitors of cyclin-dependent kinase identified at BMS

Recent patent covers new platelet ADP receptor antagonists synthesized at Cor

NDA for Vanlev to be refiled by Bristol-Myers Squibb

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...